Last €7.77 EUR
Change Today +0.58 / 8.07%
Volume 942.4K
IPH On Other Exchanges
Symbol
Exchange
EN Paris
Frankfurt
OTC US
As of 11:37 AM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

innate pharma sa (IPH) Snapshot

Open
€7.29
Previous Close
€7.19
Day High
€7.90
Day Low
€7.25
52 Week High
02/12/14 - €12.30
52 Week Low
11/25/13 - €3.29
Market Cap
411.5M
Average Volume 10 Days
292.3K
EPS TTM
€-0.20
Shares Outstanding
53.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INNATE PHARMA SA (IPH)

Related News

No related news articles were found.

innate pharma sa (IPH) Related Businessweek News

No Related Businessweek News Found

innate pharma sa (IPH) Details

Innate Pharma S.A., a biopharmaceutical company, is engaged in the research and development of pharmaceutical products primarily immunotherapy drug candidates for cancer and inflammatory diseases in France. The company develops monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its product candidates in clinical development comprise Lirilumab (IPH2102/BMS-986015), a monoclonal antibody (IgG4) blocking killer-cell immunoglobulin-like receptors in Phase II clinical trials for cancer and two Phase I clinical trials to solid tumors in combination with ipilimumab and nivolumab; and IPH2201, an IgG4 antibody, which is in Phase I clinical trials for the treatment of rheumatoid arthritis. The company is also involved in the pre-clinical development of IPH4102, a cytotoxic mAb that targets KIR3DL2. In addition, it is engaged in IPH33 program, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH43 program for the development of anti-MICA therapeutic antibody in oncology. It has licensing agreements with Bristol-Myers Squibb and Novo Nordisk A/S. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseilles, France.

90 Employees
Last Reported Date: 09/19/14
Founded in 1999

innate pharma sa (IPH) Top Compensated Officers

Co-Founder, Chairman of Executive Board and C...
Total Annual Compensation: €305.2K
Co-Founder and Member of Scientific Advisory ...
Total Annual Compensation: €214.0K
Executive Vice-President, Senior Advisor Fina...
Total Annual Compensation: €244.5K
Compensation as of Fiscal Year 2013.

innate pharma sa (IPH) Key Developments

Innate Pharma S.A. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 08:40 AM

Innate Pharma S.A. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 08:40 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Innate Pharma SA Announces Peer-Reviewed Scientific Article Describing IPH4102 and Results of Preclinical Efficacy Studies

Innate Pharma SA announced that a peer-reviewed scientific article describing IPH4102 and results of preclinical efficacy studies was published online in Cancer Research, a journal of the American Association for Cancer Research. The article published is entitled 'IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma'. Potent antitumor properties of IPH4102 were shown against human cutaneous T-cell lymphoma (CTCL) cells in vitro and in vivo in a mouse model of KIR3DL2+ tumors, in which IPH4102 reduced tumor growth and improved survival. The efficacy of IPH4102 was further evaluated in laboratory assays using the patients' own natural killer (NK) cells against their primary tumor samples in presence of IPH4102. These latter studies were performed in patients with Sézary Syndrome, the leukemic form of CTCL with the worst prognosis. In these experiments, IPH4102 selectively and efficiently induced killing of the patients' CTCL cells. Together, these results provide preclinical proof of concept supporting the clinical development of IPH4102 to treat advanced CTCL patients.

Innate Pharma S.A. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2014

Innate Pharma S.A. reported consolidated earnings results for the six months ended June 30, 2014. For the period, the company's current revenue and other income was EUR 4,137,000 compared with EUR 6,978,000 a year ago. A decrease in revenue and other income was mainly due to the decrease in the recognition of the upfront payment from the licensing deal with Bristol-Myers Squibb. Operating loss was EUR 9,063,000 compared with EUR 2,177,000 a year ago. Net loss was EUR 9,039,000 or EUR 0.19 per basic and diluted share compared with EUR 2,323,000 or EUR 0.06 per basic and diluted share a year ago. The net cash flow used in operating activities was EUR 8,759,000, compared to EUR 7,964,000 for the same year-ago period. Acquisition of property, plant and equipment was EUR 230,000, compared to EUR 259,000 for the same year-ago period. Acquisition of intangible assets was EUR 2,023,000. The cash flow generated during the period under review mainly resulted from a loss of EUR 9.0 million for the six-month period ended June 30, 2014, including amortization for an amount of EUR 1.1 million, the net proceed from a capital increase completed in June 2014 subscribed by specialist institutional investors for an amount of EUR 47.8 million, the acquisition of the anti-NKG2A antibody from Novo Nordisk A/S, the acquisition of current financial assets and the net proceed from the issuance of new shares corresponding to the exercise of equity instruments.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPH:FP €7.77 EUR +0.58

IPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPH.
View Industry Companies
 

Industry Analysis

IPH

Industry Average

Valuation IPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.1x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNATE PHARMA SA, please visit www.innate-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.